ClinicalTrials.gg

Program

ETBX-071

Also written as “ETBX-071 (PSA-based Oncolytic Virus)”.

Its studies are mostly in Prostatic Neoplasms, led by ImmunityBio.

Furthest: phase 2, since Dec 20, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ImmunityBio20 open or runningphase 2since Dec 20, 2024Dec 20, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2024First studies: 2 phase 2 studies in Prostatic NeoplasmsFirst studyNCT06765954, NCT06765902

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06765902Prostatic Neoplasms2WithdrawnJan 31, 20310
NCT06765954Prostatic Neoplasms2WithdrawnJan 31, 20310

How it is read

Names in the registry

  • “ETBX-071”, 1 entry
  • “ETBX-071 (PSA-based Oncolytic Virus)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.